FDA Approves First Anti-inflammatory Drug for Cardiovascular Disease
In June 2023, the FDA approved Lodoco to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients. Lodoco is the first drug approved to target inflammation that is an underlying cause of atherosclerotic cardiovascular disease.
FDA Approves Pfizer’s Alopecia Drug
The FDA in June 2023 approved Pfizer’s Litfulo (ritlecitinib), a once-daily oral treatment, for people 12 years of age and older with severe alopecia. It has an annual list price of Litfulo is $49,000.
FDA Approves First Drug for Geographic Atrophy Due to AMD
The FDA approved Syfovre in February 2023 with a list price of $2,190 per vial,
New Pediatric Growth Hormone Therapy Costs $8,300 Monthly
Ngenla (somatrogon-ghla), approved by the FDA in June 2023 is a once-weekly, human growth hormone analog for pediatric patients 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone.
FDA Approves Xdemvy for Eye Infection Caused by Mites
Xdemvy, approved in July, is the first treatment that directly targets the mites involved in the Demodex blepharitis. It has list price of $1,850 per prescription.
GSK’s Arexvy is First RSV Vaccine Approved for Older Adults
Approved in May, Arexvy prevents lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More